



Website: www.innovationbioscience.com

E-mail: inquire@munevarassociates.com

Phone: (800) 975-6853

Introduction:

Innovation Bioscience is a Munevar & Associates, Inc., training and incubation initiative focused on bridging the gap between biomedical research and healthcare need. Life science professionals are well positioned to be domain-expert entrepreneurs filling a much-needed gap in translation and commercialization. Entrepreneurship can be an attractive career track for some, but many lack the background and experience necessary to engage with new venture creation opportunities.

Our program introduces participants to the foundational entrepreneurial and business concepts needed to transfer technologies from ideation to a viable commercial business opportunity. Through an intense experiential training and project driven approach, we seek to provide biomedical researchers and clinicians (*among others*) with the training and resources needed to help bridge the research bench to patient bedside.

Program Highlights to Date:

- *Life Science Professional Trained to Date: ~ 75*
- *Life Science Professional Parent Institutions:* Boston Children's Hospital, Harvard Medical School, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Broad Institute, and Addgene
- *Professional Background:* PhD's, MD's, MD/PhD's
- *Virtual Incubator Outcomes (selected):* Boston Pediatric Device Strategic Partner Challenge award recipient, Boston Pediatric Device Consortium award recipient, Biopharma/start-up development agreement, novel therapeutic start-up nucleated with Dr. George Church (others)

The *Introduction to Life Science Commercialization* program takes participants through an intense, experiential, and team based approach to lean venture creation and business communication leveraging existing intellectual property. Below is a highlight of new venture proposals that resulted from the first three cohorts:

- Smart gel based extended delivery system for rheumatoid arthritis therapeutics.
- Screening and development of novel adjuvant(s) molecules for improved vaccine efficacy.
- Intracranial stimulation and patient data collection for alleviating treatment resistant depression.
- Bi-specific antibody based cancer therapeutic targeting CD47 for a variety of cancer types.
- Novel wearable aggregated technology for monitoring cardiac diseases, specifically congestive heart failure.
- Metabolic sensing wearable for easy, accurate, measurement of exercise levels to help users maximize exercise efficiency and avoid injury.
- Long-term drug-eluting contact lens for the safe and accurate drug delivery that is rapid, easy to deploy, and will ensure proper patient/drug compliance.
- A surgical device for rapid intracranial pressure relief following injury. Portable, battery operated, drilling device that can relieve high pressure from the cranium following trauma by trained non-neurosurgical personnel while en route to long distance healthcare facilities.
- Collagen 23 biomarker based cancer diagnostic allowing for rapid and sensitive urinary diagnostic for non-small cell lung cancer and prostate cancer.
- Synthetic probiotics that can convert intestinal ammonia into an amino acid, which is flushed out of the body through the stool, specifically for Urea Cycle Disorders and hepatic encephalopathy.
- Application of mTOR phospho-proteome signature to predict the effect of mTOR inhibitors, specifically in kidney cancer.
- Alkaline Phosphatase Treatment: neutralizing bacterial toxins to improve the outcome of burn injuries.